TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Clene ( (CLNN) ).
On December 3, 2025, Clene Inc. hosted a conference call and webcast to provide an update on its CNM-Au8® program for amyotrophic lateral sclerosis (ALS). This event reflects the company’s ongoing efforts to advance its therapeutic solutions in the treatment of ALS, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high net losses, and negative equity. While technical analysis shows some positive momentum, the negative P/E ratio and lack of dividend yield further weigh down the score.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Average Trading Volume: 121,097
Technical Sentiment Signal: Buy
Current Market Cap: $98.79M
For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.